NLTX Annual Book Value
$94.33 M
-$48.53 M-33.97%
31 December 2022
Summary:
As of February 5, 2025, NLTX annual book value is $94.33 million, with the most recent change of -$48.53 million (-33.97%) on December 31, 2022. During the last 3 years, it has fallen by -$47.36 million (-33.42%).NLTX Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly Book Value
$75.23 M
-$4.34 M-5.46%
30 September 2023
Summary:
As of February 5, 2025, NLTX quarterly book value is $75.23 million, with the most recent change of -$4.34 million (-5.46%) on September 30, 2023. Over the past year, it has dropped by -$30.41 million (-28.79%).NLTX Quarterly Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Book Value Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -34.0% | -28.8% |
3 y3 years | -33.4% | -62.5% |
5 y5 years | -4.6% | -1.9% |
NLTX Book Value High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | ||||
5 y | 5-year | ||||
alltime | all time | -50.7% | -62.4% |
Neoleukin Therapeutics Book Value History
Date | Annual | Quarterly |
---|---|---|
Sept 2023 | - | $75.23 M(-5.5%) |
June 2023 | - | $79.58 M(-2.2%) |
Mar 2023 | - | $81.36 M(-13.8%) |
Dec 2022 | $94.33 M(-34.0%) | $94.33 M(-10.7%) |
Sept 2022 | - | $105.65 M(-9.5%) |
June 2022 | - | $116.71 M(-10.3%) |
Mar 2022 | - | $130.09 M(-8.9%) |
Dec 2021 | $142.86 M(-25.3%) | $142.86 M(-7.7%) |
Sept 2021 | - | $154.87 M(-7.3%) |
June 2021 | - | $167.07 M(-6.6%) |
Mar 2021 | - | $178.97 M(-6.4%) |
Dec 2020 | $191.22 M(+35.0%) | $191.22 M(-4.6%) |
Sept 2020 | - | $200.34 M(+55.7%) |
June 2020 | - | $128.70 M(-6.1%) |
Mar 2020 | - | $137.12 M(-3.2%) |
Dec 2019 | $141.69 M(+95.0%) | $141.69 M(+111.9%) |
Sept 2019 | - | $66.88 M(-7.5%) |
June 2019 | - | $72.33 M(+1.1%) |
Mar 2019 | - | $71.54 M(-1.6%) |
Dec 2018 | $72.67 M | $72.67 M(-5.3%) |
Date | Annual | Quarterly |
---|---|---|
Sept 2018 | - | $76.72 M(-15.4%) |
June 2018 | - | $90.68 M(+5.7%) |
Mar 2018 | - | $85.83 M(-13.2%) |
Dec 2017 | $98.89 M(-31.6%) | $98.89 M(-13.3%) |
Sept 2017 | - | $114.09 M(-8.4%) |
June 2017 | - | $124.61 M(-9.0%) |
Mar 2017 | - | $136.94 M(-5.3%) |
Dec 2016 | $144.66 M(+33.4%) | $144.66 M(-6.9%) |
Sept 2016 | - | $155.36 M(+68.7%) |
June 2016 | - | $92.09 M(-10.1%) |
Mar 2016 | - | $102.39 M(-5.6%) |
Dec 2015 | $108.42 M(+199.9%) | $108.42 M(-4.9%) |
Sept 2015 | - | $114.03 M(+341.8%) |
June 2015 | - | $25.81 M(-14.2%) |
Mar 2015 | - | $30.08 M(-16.8%) |
Dec 2014 | $36.15 M(-155.0%) | $36.15 M(-17.8%) |
Sept 2014 | - | $43.98 M(-12.1%) |
June 2014 | - | $50.02 M(-9.2%) |
Mar 2014 | - | $55.10 M(-183.9%) |
Dec 2013 | -$65.69 M(+28.6%) | -$65.69 M |
Dec 2012 | -$51.10 M | - |
FAQ
- What is Neoleukin Therapeutics annual book value?
- What is the all time high annual book value for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual book value year-on-year change?
- What is Neoleukin Therapeutics quarterly book value?
- What is the all time high quarterly book value for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly book value year-on-year change?
What is Neoleukin Therapeutics annual book value?
The current annual book value of NLTX is $94.33 M
What is the all time high annual book value for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual book value is $191.22 M
What is Neoleukin Therapeutics annual book value year-on-year change?
Over the past year, NLTX annual book value has changed by -$48.53 M (-33.97%)
What is Neoleukin Therapeutics quarterly book value?
The current quarterly book value of NLTX is $75.23 M
What is the all time high quarterly book value for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly book value is $200.34 M
What is Neoleukin Therapeutics quarterly book value year-on-year change?
Over the past year, NLTX quarterly book value has changed by -$30.41 M (-28.79%)